Axol Bioscience launches new iPSC-derived astrocyte kits

Axol Bioscience has announced the launch of a new range of induced pluripotent stem cell (iPSC)-derived astrocyte kits.

The company's new iPSC-derived astrocyte progenitor kit and iPSC-derived mature astrocyte kit include cryopreserved cells, optimised media and supplements, and have a number of applications in the field of neuroscience research.

They provide a complete culture system that is easy to use and promotes long-term cell viability for disease modelling and drug discovery applications, with particular benefits for studying central nervous system disorders such as Alzheimer's and Parkinson's diseases, as well as autism, amyotrophic lateral sclerosis, Rett syndrome and schizophrenia.

The kits make it possible to study astrocytes as an isolated population or in combination with neurons for more complex analysis of the central nervous system.

Dr Yichen Shi, chief executive officer of Axol Bioscience, said: "The addition of these kits will help to establish our growing reputation as a global leader in the supply of human iPSC-derived cells for neurological studies."

It is hoped that the availability of these kits will advance understanding of disease development, onset and drug response.